↓ Skip to main content

STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study

Overview of attention for article published in Journal of Autism & Developmental Disorders, November 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter
5 tweeters
patent
2 patents
googleplus
1 Google+ user

Citations

dimensions_citation
62 Dimensions

Readers on

mendeley
102 Mendeley
Title
STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study
Published in
Journal of Autism & Developmental Disorders, November 2013
DOI 10.1007/s10803-013-1963-z
Pubmed ID
Authors

Craig A. Erickson, Jeremy M. Veenstra-Vanderweele, Raun D. Melmed, James T. McCracken, Lawrence D. Ginsberg, Linmarie Sikich, Lawrence Scahill, Maryann Cherubini, Peter Zarevics, Karen Walton-Bowen, Randall L. Carpenter, Mark F. Bear, Paul P. Wang, Bryan H. King

Abstract

STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder-Not Otherwise Specified, and a score ≥17 on the Aberrant Behavior Checklist (ABC)-Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCS-PDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 102 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 2%
Spain 1 <1%
Unknown 99 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 19 19%
Student > Master 18 18%
Student > Ph. D. Student 15 15%
Unspecified 11 11%
Student > Bachelor 9 9%
Other 30 29%
Readers by discipline Count As %
Medicine and Dentistry 22 22%
Psychology 22 22%
Agricultural and Biological Sciences 17 17%
Unspecified 13 13%
Neuroscience 6 6%
Other 22 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 March 2017.
All research outputs
#2,121,355
of 12,316,253 outputs
Outputs from Journal of Autism & Developmental Disorders
#1,110
of 3,051 outputs
Outputs of similar age
#36,525
of 210,526 outputs
Outputs of similar age from Journal of Autism & Developmental Disorders
#40
of 98 outputs
Altmetric has tracked 12,316,253 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,051 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 210,526 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.